Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0JY1I
|
|||
| Drug Name |
PMID25656651-Compound-19a
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
4SC AG [DE]
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H21N5O3S
|
|||
| Canonical SMILES |
CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)C=CC(=O)NO)NC3=NC(=CS3)C4=CN=CC=C4
|
|||
| InChI |
1S/C25H21N5O3S/c1-16-4-10-20(27-24(32)18-8-5-17(6-9-18)7-11-23(31)30-33)13-21(16)28-25-29-22(15-34-25)19-3-2-12-26-14-19/h2-15,33H,1H3,(H,27,32)(H,28,29)(H,30,31)/b11-7+
|
|||
| InChIKey |
OINCRSHJNMRVSX-YRNVUSSQSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Fusion protein Bcr-Abl (Bcr-Abl) | Target Info | Inhibitor | [1] |
| Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) | Target Info | Inhibitor | [1] | |
| Target's Patent Info | Fusion protein Bcr-Abl (Bcr-Abl) | Target's Patent Info | [1] | |
| Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) | Target's Patent Info | [1] | ||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.